This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Poniard, Netlist: Early Volume Plays

NEW YORK (TheStreet) -- Several stocks trading under $5 were poised to move on above-average volume during Wednesday's session.

Poniard Pharmaceuticals (PARD) rose by 18 cents, or 7.3%, to $2.66 in the premarket session one day after the company said current study data shows a combination of its drug candidate picoplatin and chemotherapy works about as well as a standard chemotherapy regimen as a treatment for colorectal cancer. On Monday, Poniard disclosed the failed phase III study of picoplatin in small cell lung cancer. The 50-day average daily volume for Poniard is 2.2 million, according to the Nasdaq.

China Sunergy (CSUN) jumped by 37 cents, or 8.8%, to $4.60 in the premarket session after the company reported third-quarter adjusted earnings of 19 cents a share, well ahead of the Thomson Reuters average estimate of 2 cents a share. Full-year shipments will be between 190 megawatts of solar cells to 200 MW, which is at the high end previous guidance range. The 50-day average daily volume for China Sunergy is 304,000, according to the Nasdaq.

Netlist (NLST) gained 30 cents, or 7.3%, to $4.40 in the premarket session, continuing the recently rally sparked by the introduction of the company's HyperCloud product, the first 16-gigabyte, 2 vRank memory module for computer servers. The 50-day average daily volume for Netlist is 1.1 million, according to the Nasdaq.

Oncolytics Biotech (ONCY) plummeted by 55 cents, or 16%, to $2.88 in the premarket session after the company late Tuesday announced a unit offering. The number and the price of each unit, as well as the exercise price of each warrant, will be determined in the context of the market with final terms to be determined at the time of pricing, the company said. Oncolytics intends to use the net proceeds from the offering to fund its previously announced phase III combination Reolysin, a treatment for head and neck cancer. The 50-day average daily volume for Oncolytics is 218,000, according to the Nasdaq.

Boise (BZ) gave back 11 cents, or 2.2%, to $4.98 in the premarket session after the company late Tuesday said its secondary offering of 17 million shares of its common stock has been priced at $4.85 a share. The three-month average daily volume for Boise is 1.2 million, according to Yahoo! Finance.

-- Written by Robert Holmes in New York.

Check out all of Wednesday's high-volume, under-$5 stocks at the Dollar Store

Follow Robert Holmes on Twitter and become a fan of TheStreet.com on Facebook.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,960.57 -123.23 -0.72%
S&P 500 1,978.34 -9.64 -0.48%
NASDAQ 4,449.5640 -22.5440 -0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs